/ /

  • linkedin
  • Increase Font
  • Sharebar

    MIGS driving the device market



    The Xen gelatin stent finished enrollment on its first IDE study in the United States and is enrolling patients for its second IDE trial. Clinical trial data collected on the soft gelatin stent are uniformly encouraging.

    “We reduce IOP toward the mid-teens and we are getting significant reductions in glaucoma medication use,” said Barbara Niksch, vice president for clinical and regulatory affairs. “Once we get a month out from implantation, pressures are stable. In the longer term, we are seeing low- to mid-teen IOPs plus continuing medication reduction.”

    Xen is a soft, compressible and tissue-conforming stent, designed to mitigate traditional implant issues. The device and its pre-loaded injector can be used with or without cataract surgery. The stent creates an ab interno bleb and drains aqueous using the subconjunctival outflow pathway. Mean IOP drops about 30% from baseline in early generation devices and close to 40% using the latest version plus mitomycin C.

    “This is direct subconjunctival outflow that bypasses all potential outflow obstructions,” she said. “There is absolute certainty of outflow and a single implant delivers the desired efficacy. Our international studies demonstrate success in all stages of glaucoma.”

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results